SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  SCHEDULE 13G/A

                    Under the Securities Exchange Act of 1934
                          (Amendment No.___8__)*


                              Enzo Biochem, Inc.
              -----------------------------------------------------
                                (Name of Issuer)

                           Common Stock, $.01 par value
          -------------------------------------------------------------
                         (Title of Class of Securities)

                                294100102
              -----------------------------------------------------
                                 (CUSIP Number)



Check the following box if a fee is  being paid with this statement [ ].

(A fee is not required only if the filing person:  (1) has a previous  statement
on file reporting beneficial ownership of more than five percent of the class of
securities  described  in Item 1;  and (2) has  filed  no  amendment  subsequent
thereto reporting  beneficial  ownership of five percent or less of such class.)
(See Rule 13d-7.)

*The  remainder of this cover page shall be filled out for a reporting  person's
initial filing on this form with respect to the subject class of securities, and
for any  subsequent  amendment  containing  information  which  would  alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the  Securities  Exchange  Act of
1934 ("Act") or otherwise  subject to the liabilities of that section of the Act
but  shall be  subject  to all other  provisions  of the Act  (however,  see the
Notes).

Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

[] Rule 13d-1(b)

[x] Rule 13d-1(c)

[ ] Rule 13d-1(d)


* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).


                        Page 1 of 5 pages




CUSIP No. 294100102                  13G/A                   Page 2 of 5 Pages



--------------------------------------------------------------------------------
   1   NAME OF REPORTING PERSON
       S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

       J. Morton Davis


--------------------------------------------------------------------------------
   2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
                                                             (a)  [  ]
                                                             (b)  [  ]


--------------------------------------------------------------------------------
   3   SEC USE ONLY




--------------------------------------------------------------------------------
   4   CITIZENSHIP OR PLACE OF ORGANIZATION


       United States

--------------------------------------------------------------------------------
   NUMBER OF      5    SOLE VOTING POWER
     SHARES            2,942,240
  BENEFICIALLY    --------------------------------------------------------------
    OWNED BY      6    SHARED VOTING POWER
      EACH             0
   REPORTING      --------------------------------------------------------------
     PERSON       7    SOLE DISPOSITIVE POWER
      WITH             2,942,240
                  --------------------------------------------------------------
                  8    SHARED DISPOSITIVE POWER
                       0

--------------------------------------------------------------------------------
   9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON


                       2,942,240
--------------------------------------------------------------------------------
  10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*



--------------------------------------------------------------------------------
  11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)


                       7.9%
--------------------------------------------------------------------------------
  12   TYPE OF REPORTING PERSON*


                      IN
--------------------------------------------------------------------------------
                     *SEE INSTRUCTIONS BEFORE FILLING OUT


                                                          Page 3 of 5 Pages


Item 1.     (a)   Name of Issuer:

                  Enzo Biochem, Inc.

            (b)   Address of Issuer's Principal Executive Offices:

                  60 Executive Blvd
                  Farmingdale, NY  11735

Item 2.     (a)   Name of Person Filing:

                    J. Morton  Davis.


            (b)   Address of Principal Business Office:

                    Mr. Davis'  business address is 44 Wall Street,
                    New York, New York 10005 (1).

            (c)   Citizenship:

                    Mr. Davis is a United  States  citizen.

            (d)   Title of Class of Securities:

                    Common Stock, $.01 par value ("shares")

            (e)   CUSIP Number:

                    294100102


Item 3.     If this statement  is filed  pursuant to Rules  13d-1(b), or
            13d-2(b), check whether the person filing is a:

            (a)   [ ]   Broker or Dealer  registered under Section  15 of  the
                        Act

            (b)   [ ]   Bank as defined in section 3(a)(6) of the Act

            (c)   [ ]   Insurance Company  as defined  in section  3(a)(19) of
                        the Act

            (d)   [ ]   Investment Company registered under  section 8 of  the
                        Investment Company Act

            (e)   [ ]   Investment Adviser registered under section 203 of the
                        Investment Advisers Act of 1940

            (f)   [ ]   Employee Benefit Plan,  Pension Fund which is  subject
                        to the  provisions of  the Employee Retirement  Income
                        Security Act of  1974 or Endowment  Fund; see  Section
                        240.13d-1(b)(1)(ii)(F)

            (g)   [ ]   Parent  Holding  Company, in  accordance  with Section
                        240.13d-1(b)(1)(ii)(G)

            (h)   [ ]   Group,   in   accordance    with   Section    240.13d-
                        1(b)(1)(ii)(H)

            (i)   [ ]   A church plan that is excluded from definition of an
                        investment company under section 3(c) (14) of the
                        Investment Company Act of 1940.



______________________________________________________________________________
(1) J. Morton Davis is the sole  shareholder  of D.H. Blair  Investment  Banking
Corp ("Blair  Investment").




                                                             Page 4 of 5 Pages
 Item 4.     Ownership.


 (a)  (b) As of December 31, 2008, Mr.  Davis may be deemed to  beneficially
          own (1)  2,942,240  shares or 7.9% of the Issuer's  shares issued and
          outstanding  as follows (i) 33,425 shares owned directly by Mr. Davis,
          (ii)  1,024,345  shares  owned  directly  by Blair  Investment,  (iii)
          691,396  shares owned by Engex,  Inc. (2), (iv) 12,733 shares owned by
          an investment  advisor whose principal is Mr. Davis, and (v) 1,180,341
          shares owned by Rosalind Davidowitz, Mr. Davis' wife (3).

     (c)  Mr. Davis has sole power to vote or to direct the vote,  to dispose or
          to direct the  disposition of those shares owned by Blair  Investment.
          Rosalind  Davidowitz  has  sole  power to  dispose  or to  direct  the
          disposition  of those  shares  owned  directly by her.  Voting and
          dispositive  decisions regarding shares owned by Engex are made by Mr.
          Davis as Chairman of the Board.

Item 5.   Ownership of Five Percent of class.

            Not applicable.

Item 6.     Ownership of More Than Five Percent on Behalf of Another Person.

            Not applicable.


Item 7.     Identification and Classification of the Subsidiary which Acquired
            the Security Being Reported on By the Parent Holding Company.

            Not applicable.

Item 8.     Identification and Classification of Members of the Group.

            Not applicable.

    __________________________________________________________________________


     (1)  Not  included  herein are  shares  owned by Kinder  Investments,  L.P.
          ("Kinder"), shares owned by Venturetek, L.P. ("Venturetek") and shares
          owned by Sutton  Partners,  L.P.  ("Sutton").  The limited partners of
          Kinder,  Venturetek,  and Sutton are the children and grandchildren of
          Mr. Davis. Mr. Davis disclaims for purposes of Section 13 or otherwise
          beneficial ownership of any Enzo Biochem, Inc. shares owned by Kinder,
          Venturetek  and Sutton.  Kinder,  Venturetek  and Sutton  disclaim for
          purposes of Section 13 or  otherwise  ownership  of any Enzo  Biochem,
          Inc. shares owned by Blair Investment or Mr. Davis.

     (2)  Engex,  Inc.  ("Engex")  is an  investment  company  registered  under
          Section 8 of the  Investment  Company Act. Mr. Davis is reporting as a
          beneficial  owner of the securities owned by Engex because of his role
          as Chairman of Engex.  Filing of this statement shall not be deemed an
          admission by J. Morton Davis that he beneficially  owns the securities
          attributed  to  Engex  for any  purpose.  J.  Morton  Davis  expressly
          disclaims beneficial ownership of all securities held by Engex for any
          purpose.

     (3)  Filing of this statement shall not be deemed an admission by J. Morton
          Davis  that he  beneficially  owns the  securities  attributed  to Ms.
          Davidowitz  for any  purpose.  J.  Morton  Davis  expressly  disclaims
          beneficial  ownership of all securities held by Ms. Davidowitz for any
          purpose.




                                                            Page 5 of 5 pages

Item 9.     Notice of Dissolution of Group.

            Not applicable.

Item 10.    Certification.

     By signing below I certify that, to the best of my knowledge and belief,
the  securities  referred  to above  were  acquired  in the  ordinary  course of
business  and were not acquired for the purpose of and do not have the effect of
changing or  influencing  the control of the issuer of such  securities and were
not acquired in connection  with or as a participant in any  transaction  having
such purpose or effect.
                                   Signature.


     After  reasonable  inquiry and to the best of my knowledge and belief, I
certify that the information  set forth in this statement is true,  complete and
correct.





Date: February 10, 2009



By: /s/ J. Morton Davis
   -------------------------------
    J. Morton Davis